Core Viewpoint - Arcosa (ACA) shows potential for significant upside, with a mean price target of $109.20 indicating a 26.5% increase from its current price of $86.33 [1] Price Targets - The average price target consists of five estimates ranging from $100 to $120, with a standard deviation of $7.29, suggesting a consensus among analysts [2] - The lowest estimate indicates a 15.8% increase, while the highest suggests a 39% upside [2] Analyst Sentiment - Analysts exhibit strong agreement on ACA's earnings prospects, with positive revisions in earnings estimates supporting the potential for stock price increases [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.4%, with one estimate increasing and no negative revisions [12] Zacks Rank - ACA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Entel SA (ENTEL.SN) Trimming Estimates Post-1Q25 27 May 2025 | 5:20PM BRT | ENTEL.SN | | --- | | 12m Price Target: Ch$3,450 | | Price: Ch$2,791 | | Upside: 23.6% | We incorporate 1Q25 earnings as well as updated macro/FX assumptions, lowering estimates particularly in Chile, given i) somewhat more-conservative ARPU assumptions amid continued competitive pressure from AMX and WOM in mobile, though we already assumed some increased competition this year; ii) weaker-than-expected fiber trends, with management ...

Core Viewpoint - GeneDx Holdings Corp. (WGS) shows potential for significant upside, with a mean price target of $92.86 indicating a 32.6% increase from the current price of $70.02 [1] Price Targets and Analyst Estimates - The mean estimate consists of seven short-term price targets with a standard deviation of $15.09, indicating variability among analysts [2] - The lowest estimate of $78 suggests an 11.4% increase, while the highest estimate of $114 indicates a potential surge of 62.8% [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about WGS's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 12.4%, with no negative revisions [12] - WGS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13]

Core Viewpoint - Centerra Gold Inc. (CGAU) has seen a 2.8% increase in share price over the past four weeks, closing at $6.88, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $8.76, representing a 27.3% upside [1] Price Targets and Analyst Consensus - The average price target consists of 11 estimates ranging from a low of $6.50 to a high of $11, with a standard deviation of $1.19, indicating variability among analysts [2] - The lowest estimate suggests a decline of 5.5% from the current price, while the highest estimate indicates a potential upside of 59.9% [2] - A low standard deviation signifies greater agreement among analysts regarding price movement, which can be a useful starting point for further research [9] Earnings Estimates and Potential Upside - Analysts show strong agreement in revising CGAU's earnings estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, four estimates have increased while one has decreased, leading to a 31.6% rise in the Zacks Consensus Estimate for the current year [12] - CGAU holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Core Viewpoint - North American Construction (NOA) has shown a significant price increase of 11.1% over the past four weeks, with a mean price target of $25.70 indicating a potential upside of 51.1% from its current price of $17.01 [1] Price Targets and Analyst Consensus - The average price target for NOA ranges from a low of $19.46 to a high of $31.68, with a standard deviation of $3.99, suggesting a variability in analyst estimates [2] - The lowest estimate indicates a 14.4% increase, while the highest suggests an 86.2% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about NOA's earnings prospects, as indicated by a trend of upward revisions in earnings estimates [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 1.3%, with one estimate moving higher and no negative revisions [12] - NOA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - Olema Pharmaceuticals, Inc. (OLMA) shows significant upside potential with a mean price target of $24.71, indicating a 386.4% increase from the current price of $5.08 [1] Price Targets - The average price target consists of seven estimates ranging from a low of $18 to a high of $30, with a standard deviation of $4.64, suggesting variability in analyst opinions [2] - The lowest estimate indicates a potential increase of 254.3%, while the highest suggests a 490.6% upside [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts are optimistic about OLMA's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 25.4%, with five estimates moving higher and no negative revisions [12] Zacks Rank - OLMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13]

Core Viewpoint - SkyWater Technology, Inc. (SKYT) shows significant potential for upside, with a mean price target of $11 indicating a 35% upside from its current price of $8.15, following a 23.7% gain over the past four weeks [1]. Price Targets and Analyst Consensus - The average price targets from analysts range from a low of $8 to a high of $12, with a standard deviation of $1.73, indicating variability in estimates. The lowest estimate suggests a decline of 1.8%, while the highest points to a 47.2% upside [2]. - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding SKYT's earnings prospects, as indicated by a positive trend in earnings estimate revisions. This trend has a strong correlation with near-term stock price movements [11]. - Over the last 30 days, two earnings estimates for SKYT have been revised upward, leading to a 20.8% increase in the Zacks Consensus Estimate [12]. Zacks Rank and Investment Potential - SKYT holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, which further supports its potential for upside [13].

Core Viewpoint - Encore Capital Group (ECPG) has shown a significant price increase of 38.2% over the past four weeks, with a mean price target of $58.50 indicating a potential upside of 44.4% from the current price of $40.51 [1] Price Targets and Analyst Consensus - The average price target for ECPG ranges from a low of $55 to a high of $66, with a standard deviation of $5.07, suggesting a relatively high agreement among analysts [2] - The lowest estimate indicates a potential increase of 35.8%, while the most optimistic estimate suggests a 62.9% upside [2] - Analysts' price targets should be approached with caution, as they may not always accurately reflect future stock movements [3][7] Earnings Estimates and Analyst Optimism - Analysts have shown strong agreement in revising ECPG's earnings estimates higher, which is a positive indicator for potential stock upside [4][11] - The Zacks Consensus Estimate for the current year has increased by 11.8% over the past month, with three estimates revised upward and no negative revisions [12] - ECPG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Investment Potential - While the consensus price target may not be a reliable indicator of the extent of ECPG's potential gains, the direction implied by these targets appears to be a useful guide for further research [13]

Shares of Amneal Pharmaceuticals (AMRX) have gained 7% over the past four weeks to close the last trading session at $7.46, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $11.50 indicates a potential upside of 54.2%.The mean estimate comprises four short-term price targets with a standard deviation of $0.58. While the lowest estimate of $11 indicates a 47.5% increase from the c ...

Group 1 - Pfizer (PFE) closed at $22.79, with a 1.3% gain over the past four weeks, and a mean price target of $28.52 indicating a 25.1% upside potential [1] - The average of 21 short-term price targets ranges from $23 to $35, with a standard deviation of $3.16, suggesting variability in analyst estimates [2] - Analysts have shown increasing optimism about PFE's earnings prospects, with a 3.2% increase in the Zacks Consensus Estimate for the current year and no negative revisions [12][11] Group 2 - The Zacks Rank for PFE is 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - A tight clustering of price targets, indicated by a low standard deviation, suggests a high degree of agreement among analysts regarding the stock's price movement [9] - While price targets can be misleading, the direction implied by them may serve as a useful guide for further research into the stock's potential [10][7]